Masimo (MASI)
(Delayed Data from NSDQ)
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Zacks News
Masimo (MASI) O3 Regional Oximetry Device Gets FDA Nod
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of FDA 510(k) clearance for O3 regional oximetry device.
Masimo (MASI) Beats on Q1 Earnings and Revenues, Guides Up
by Zacks Equity Research
Masimo Corp. (MASI) reported earnings of 57 cents per share in the first quarter of 2017, outperforming the Zacks Consensus Estimate of 54 cents and improving from the year-ago quarterly earnings of 53 cents.
Zacks.com featured highlights: Ituran Location and Control, Molina Healthcare, WellCare Health Plans and Masimo
by Zacks Equity Research
Zacks.com featured highlights: Ituran Location and Control, Molina Healthcare, WellCare Health Plans and Masimo
4 Top-Ranked Liquid Stocks for a Winning Portfolio
by Zacks Equity Research
Liquidity of a stock primarily indicates a company's capability to meet debt obligations by converting assets into liquid cash and equivalents.
After ISRG Q1 Earnings, 3 Medical Instrument Stocks Looking Up
by Zacks Equity Research
While the Medical Instrument industry has been oscillating between hope and despair, let us take a look at three stocks which are expected to put up an impressive show this earnings season like Intuitive Surgical.
Masimo (MASI) Launches Root Platform with Kite Trademark
by Zacks Equity Research
Irvine, CA-based Masimo Corporation (MASI) announced full market release of the Root monitoring platform with a Kite trademark (a supplementary display system).
Obamacare Holds Ground: 3 Medical Device Stocks to Gain
by Zacks Equity Research
Republican leaders have failed to play their "Trump card" this time, courtesy of the pullback of the Republican healthcare bill, the American Health Care Act (ACHA), which was designed to repeal the Affordable Care Act (ACA) or Obamacare.
Masimo (MASI) Up 20.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Medical Device Stocks to Brave Policy Uncertainty
by Zacks Equity Research
We believe stocks with strong fundamentals that also have a significant share of their business overseas may well brace themselves in the on-going conundrum. They will make lucrative additions to your portfolio.
Can The Uptrend Continue for Masimo (MASI)?
by Zacks Equity Research
Investors certainly have to be happy with Masimo Corporation (MASI) and its short term performance
Masimo Announces Availability of RD SedLine Brain Sensors
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the availability of the RD SedLine EEG sensor, which can be used with the company???s flagship SedLine Brain Function Monitoring technology.
Is Masimo (MASI) a Great Growth Stock?
by Zacks Equity Research
One company that might be well-positioned for future earnings growth is Masimo Corporation (MASI).
Hit ETFs & Stocks from the Top Sector of February
by Sweta Killa
Inside the best performing sector of February and their best ETFs & stocks.
Cooper (COO) to Report Q1 Earnings: Is a Surprise in Store?
by Zacks Equity Research
The Cooper Companies Inc. (COO) is set to report first-quarter fiscal 2017 results after the market closes on Mar 2.
Follow Driehaus & Pick these 5 Best-Rated Momentum Stocks
by Zacks Equity Research
Investors with high risk appetite may think of using the Driehaus strategy to boost their portfolio returns.
DexCom (DXCM) Q4 Earnings: What to Expect from the Stock?
by Zacks Equity Research
DexCom, Inc. (DXCM) is set to report fiscal fourth-quarter 2017 results on Feb 28.
Can Penumbra (PEN) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Penumbra Inc. (PEN) is slated to release fourth-quarter 2016 results on Feb 28, after market close.
Patterson Companies (PDCO) Q3 Earnings: What's in Store?
by Zacks Equity Research
Patterson Companies Inc. (PDCO) is set to report fiscal third-quarter 2017 results on Feb 23, before the opening bell.
Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
by Zacks Equity Research
Ireland-based medical device major Medtronic plc (MDT) is slated to report its third-quarter fiscal 2017 earnings on Feb 21, before the opening bell.
Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.
Masimo to Launch Advanced Monitoring Technologies in India
by Zacks Equity Research
Masimo (MASI) announced that it will launch Advanced Monitoring Technologies in the Indian market.
Masimo's (MASI) TFA-1 Forehead Sensor Gets FDA Approval
by Zacks Equity Research
Masimo Corporation (MASI) recently announced that its TFA-1 Single-Patient-Use Adhesive Forehead Sensor has received a 5I0(k) clearance from the U.S. FDA.
Masimo (MASI) Hits 52-Week High on Solid Growth Prospects
by Zacks Equity Research
Share price of Irvine, CA-based Masimo Corporation (MASI) reached a new 52-week high of $63.45 on Dec 7, finally closing a tad lower at $62.17.